AstraZeneca To "Go It Alone" For Crestor, Cites Large Market Opportunity
Executive Summary
AstraZeneca will pursue a solo marketing strategy for Crestor (rosuvastatin) based on the larger market outlined in recently issued cholesterol treatment guidelines.
You may also be interested in...
AstraZeneca Boosts Sales Productivity: Physician Office Calls Up 50%
AstraZeneca's Crestor launch will help push sales representative office visits to more than seven calls a day, a 50% increase over 2001, Senior VP-Commercial Operations Tony Zook told analysts
AstraZeneca Boosts Sales Productivity: Physician Office Calls Up 50%
AstraZeneca's Crestor launch will help push sales representative office visits to more than seven calls a day, a 50% increase over 2001, Senior VP-Commercial Operations Tony Zook told analysts
AstraZeneca Crestor NDA Includes Rhabdomyolysis Reports At Highest Dose
AstraZeneca's discussions with FDA about the safety profile of the experimental cholesterol drug Crestor (rosuvastatin) are focusing on the potential for the highest dose to cause rhabdomyolysis, the company indicated during analysts meetings the week of Dec. 3